-+ 0.00%
-+ 0.00%
-+ 0.00%

SEPTERNA ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF SEP-479, AN ORAL SMALL MOLECULE PTH1R AGONIST FOR THE TREATMENT OF HYPOPARATHYROIDISM

Reuters·04/13/2026 12:00:03

Please log in to view news